

Patient ID SA00149009	Patient Name TESTINGRNV, COGTF-ABNORMAL	Birth Date 2011-10-18	Gender M	Age 9
Order Number SA00149009	Client Order Number SA00149009	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 14 Oct 2021 06:57		

COG, ALL (T-cell), FISH

Result Summary

MCR

Abnormal

Interpretation

MCR

The result is abnormal and indicates 92% of nuclei had LMO2/TRAD fusion. At diagnosis, LMO2/TRAD fusion has been associated with an intermediate to favorable prognosis in T-lymphoblastic leukemia/lymphoma (T-ALL) (Roberts et al., Nat Rev Clin Oncol 12:344–357, 2015).

Clinical and pathologic correlation is recommended.

For monitoring response to therapy, FISH for LMO2/TRAD is available, test TALMF [ALL (T-cell), Specified FISH].

Result Table

MCR

Abnormality Name	Result	Abn%	Cutoff%
14q11.2(TRAD sep)	Abnormal	80	<15.0
t(11;14) LMO2/TRAD fusion	Abnormal	92	<4.0
t(8;14) MYC/TRAD fusion	Normal		<4.0
t(10;14) TLX1/TRAD fusion	Normal		<4.0
t(11;14) LMO1/TRAD fusion	Normal		<4.0
11q23(MLL sep)	Normal		<10.0
t(9;22) ABL1/BCR fusion	Normal		<4.0
-9p21(CDKN2Ax1,D9Z1x2)	Normal		<12.0
-9p21x2(CDKN2Ax0,D9Z1x2)	Normal		<5.0
-17p13.1(TP53x1,D17Z1x2)	Normal		<15.0
-17(TP53,D17Z1)x1	Normal		<10.0
t(5;14) TLX3/BCL11B fusion	Normal		<4.0
7q34(TRB sep)	Normal		<15.0
t(10;11) MLLT10/PICALM fusion	Normal		<4.0
1p33(TAL1/STIL sep)	Normal		<10.0

Result

MCR

nuc ish(LMO2,TRAD)x3(LMO2 con TRADx2)[184/200]

Reason for Referral

MCR

T-acute lymphoblastic leukemia; T-ALL, COG APEC14B1

Specimen

MCR

Bone Marrow

Source

MCR

Left posterior iliac crest

Method

MCR

Locus and probes	[Strategy;#Nuclei;Class]
1p33(TAL1,STIL)	[BAP;100;LDT]
5q35(TLX3), 14q32(BCL11B)	[DFISH;200;LDT]
7q34(5'TRB,3'TRB)	[BAP;100;LDT]
8q24.1(MYC), 14q11.2(TRAD)	[DFISH;200;LDT]
9p21(CDKN2A), 9CEN(D9Z1)	[COPY#;100;AM]
9q34(ABL1), 22q11.2(BCR)	[DFISH;200;AM]
10p12(MLLT10), 11q14(PICALM)	[DFISH;200;LDT]
10q24(TLX1), 14q11.2(TRAD)	[DFISH;200;LDT]
11p15(LMO1), 14q11.2(TRAD)	[DFISH;200;LDT]
11p13(LMO2), 14q11.2(TRAD)	[DFISH;200;LDT]
11q23(5'MLL[KMT2A],3'MLL[KMT2A])	[BAP;100;AM]
14q11.2(5'TRAD,3'TRAD)	[BAP;100;LDT]
17p13(TP53), 17CEN(D17Z1)	[COPY#;100;AM]

Probe strategies include:
DFISH=dual color, double fusion;
BAP=break-apart probe;
COPY#=region gain and loss.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AM = Abbott Molecular, Inc (Des Plaines, IL)

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



Patient ID SA00149009	Patient Name TESTINGRNV, COGTF-ABNORMAL	Birth Date 2011-10-18	Gender M	Age 9
Order Number SA00149009	Client Order Number SA00149009	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 14 Oct 2021 06:57		

Disclaimer

MCR

Released By

MCR

Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Jess F. Peterson, M.D.

Received: 15 Oct 2021 07:42

Reported: 25 Oct 2021 10:40

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292